Immune responses of vaccinated patients
| UPN . | Dose Level . | Number of Vaccinations . | Detectable3-150 Immunologic Response . | Clinical Outcome or Current Status (Time in Months After Vaccine) . | Reported In Vitro Response for Patient HLA Type . |
|---|---|---|---|---|---|
| 1 | 10 μg | 5 | − | PCR change;3-151 chronic phase at 33 mo | Yes; A2/DR11 |
| 2 | 10 μg | 4 | − | Chronic phase at 22 mo | Yes; A2/DR1 |
| 3 | 10 μg | 5 | − | Chronic phase at 29 mo | Unknown |
| 4 | 30 μg | 5 | − | Chronic phase at 28 mo | Yes; A11/DR3 |
| 5 | 30 μg | 5 | − | Blastic at 5 mo3-152 | Yes; A3/A24 |
| 6 | 30 μg | 5 | − | Chronic phase at 17 mo | Yes; A24/DR1 |
| 7 | 100 μg | 8 | +DTH +Proliferation | Cytogenetic change;3-153 chronic phase at 19 mo | Yes; A3 |
| 8 | 100 μg | 8 | +Proliferation | Chronic phase at 16 mo | Yes; A3/DR4 |
| 9 | 100 μg | 5 | − | Chronic phase at 5 mo | Yes; A2/DR3 |
| 10 | 300 μg | 5 | − | Accelerated phase at 11 mo | Yes; A3/A24 |
| 11 | 300 μg | 8 | +DTH +Proliferation | Chronic phase at 6 mo | Yes; A2 |
| 12 | 300 μg | 5 | − | Chronic phase at 5 mo | Yes; A2/DR4 |
| UPN . | Dose Level . | Number of Vaccinations . | Detectable3-150 Immunologic Response . | Clinical Outcome or Current Status (Time in Months After Vaccine) . | Reported In Vitro Response for Patient HLA Type . |
|---|---|---|---|---|---|
| 1 | 10 μg | 5 | − | PCR change;3-151 chronic phase at 33 mo | Yes; A2/DR11 |
| 2 | 10 μg | 4 | − | Chronic phase at 22 mo | Yes; A2/DR1 |
| 3 | 10 μg | 5 | − | Chronic phase at 29 mo | Unknown |
| 4 | 30 μg | 5 | − | Chronic phase at 28 mo | Yes; A11/DR3 |
| 5 | 30 μg | 5 | − | Blastic at 5 mo3-152 | Yes; A3/A24 |
| 6 | 30 μg | 5 | − | Chronic phase at 17 mo | Yes; A24/DR1 |
| 7 | 100 μg | 8 | +DTH +Proliferation | Cytogenetic change;3-153 chronic phase at 19 mo | Yes; A3 |
| 8 | 100 μg | 8 | +Proliferation | Chronic phase at 16 mo | Yes; A3/DR4 |
| 9 | 100 μg | 5 | − | Chronic phase at 5 mo | Yes; A2/DR3 |
| 10 | 300 μg | 5 | − | Accelerated phase at 11 mo | Yes; A3/A24 |
| 11 | 300 μg | 8 | +DTH +Proliferation | Chronic phase at 6 mo | Yes; A2 |
| 12 | 300 μg | 5 | − | Chronic phase at 5 mo | Yes; A2/DR4 |
See Table 4 and Figure 2.
PCR became negative 3 months after the end of vaccination and then reverted to positive 2 months later.
Died 3 months after the end of the protocol.
Partial and transient cytogenetic response: reduction from 30% positive metaphases to 13%. After 12 weeks after re-treatment increase to basal positive metaphases.